MENU

Published on 14/04/2021 10:35:12 AM | Source: ICICI Direct

Derivatives Strategy - Buy Biocon for target of Rs. 460 By ICICI Direct

Posted in Broking Firm Views - Short Term Report| #Biocon Ltd #Pharma Sector #Trading Report #ICICI Direct

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel  https://t.me/InvestmentGuruIndia 

Download Telegram App before Joining the Channel

Rationale

* Pharma stocks again remained one of the star performers like last year with most of them remaining in focus due to rising Covid-19 cases

* Leaders like Sun Pharma, Cipla, Dr Reddy’s and Lupin already saw positive price action whereas Biocon is one stock that largely remained under pressure below | 420 since January 2021

* In the current leg of consolidation, the stock has been hovering near its higher band of | 420 whereas it saw closure in OI, which could be a positive trigger

* Sizeable Call OI base is placed at | 420. However, short covering is likely to accelerate once the stock manages to close above this level

* Hence, we feel Biocon is likely to move towards | 460 levels for the April series with follow up buying expected in the stock. Due to uncertainty and higher volatility, we recommend forming Collar option spread where downside is protected and risk: reward remains good

 


To Read Complete Report & Disclaimer Click Here

 

https://secure.icicidirect.com/Content/StaticData/Disclaimer.html

 


Above views are of the author and not of the website kindly read disclaimer

 

marsbahis marsbahis marsbahis marsbahis
1xbet 1xbet bahisno 1 bahsegel slot oyna ecopayz güvenilir bahis siteleri canlı bahis siteleri iddaa marsbahis marsbahis marsbahis marsbahis marsbahis marsbahis marsbahis marsbahis marsbahis marsbahis marsbahis marsbahis restbet canlı skor süperbahis mobilbahis
bahigo bahis siteleri güvenilir bahis siteleri kaçak bahis siteleri betist